Acute kidney injury—an overview of diagnostic methods and clinical management

Daniel Hertzberg¹, Linda Rydén¹,², John W. Pickering³, Ulrik Sartipy⁴,⁵ and Martin J. Holzmann¹,⁶

¹Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Anesthesiology, Surgical Services and Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden, ³Department of Medicine, University of Otago Christchurch and Emergency Department, Christchurch Hospital, Christchurch, New Zealand, ⁴Section of Cardiothoracic Surgery, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden and ⁶Department of Emergency Medicine, Huddinge, Karolinska University Hospital, Stockholm, Sweden

Correspondence and offprint requests to: Martin J. Holzmann; E-mail: martin.holzmann@karolinska.se

Abstract

Acute kidney injury (AKI) is a common condition in multiple clinical settings. Patients with AKI are at an increased risk of death, over both the short and long term, and of accelerated renal impairment. As the condition has become more recognized and definitions more unified, there has been a rapid increase in studies examining AKI across many different clinical settings. This review focuses on the classification, diagnostic methods and clinical management that are available, or promising, for patients with AKI. Furthermore, preventive measures with fluids, acetylcysteine, statins and remote ischemic preconditioning, as well as when dialysis should be initiated in AKI patients are discussed. The classification of AKI includes both changes in serum creatinine concentrations and urine output. Currently, no kidney injury biomarkers are included in the classification of AKI, but proposals have been made to include them as independent diagnostic markers. Treatment of AKI is aimed at addressing the underlying causes of AKI, and at limiting damage and preventing progression. The key principles are: to treat the underlying disease, to optimize fluid balance and optimize hemodynamics, to treat electrolyte disturbances, to discontinue or dose-adjust nephrotoxic drugs and to dose-adjust drugs with renal elimination.

Key words: acute kidney injury, diagnosis, review, therapeutics

Introduction

Acute kidney injury (AKI), formerly termed acute renal failure, is characterized by a sudden deterioration in renal function [1]. Numerous studies have found that AKI is associated with an increased mortality and adverse outcomes regardless of patient characteristics and the context in which injury occurs [2, 3].

Until a decade ago, there was a lack of uniform diagnostic criteria for AKI that led to a number of various definitions being
used, making comparisons between studies difficult. In 2004, the risk, injury, failure, loss, end-stage renal disease (RIFLE) criteria for AKI was established [4]. In 2007, the AKI Network (AKIN) modified RIFLE criteria with the inclusion of an absolute change of serum creatinine (SCr) [5]. RIFLE and AKIN were later unified with the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria [1]. The KDIGO criteria define and stage patients (three severity stages) according to changes in SCr levels and urine output (Table 1).

Urinary output may be measured in real time, but commonly urine output has not been reported in studies on AKI, and thus the association between changes in urine output and outcomes in AKI are not well documented. Furthermore, it has been argued that the specificity of the urine output criteria for AKI is low, leading to many patients without AKI being misclassified to AKI [6]. However, oliguria without SCr elevation is not uncommon, and may also be associated with fluid overload where the elevation in SCr levels may be masked. Fluid overload in the context of AKI has been associated with poor outcomes [7]. Although, the KDIGO criteria for classification of AKI do not combine urine output with increases in SCr levels, there may be advantages in doing so. In a recent study, it was found that patients meeting both the SCr and urine output criteria had a dramatically worse prognosis than patients who only met either one of the two criteria [8].

The duration of injury is not included in the definition of AKI, but has been shown to be related to prognosis [9]. The term ‘acute kidney disease’ has been suggested for patients who have persistent AKI, defined as a duration >7 days, but <3 months. Thus, among patients who meet both SCr and urine output criteria for AKI, those in whom AKI is persistent have the worst prognosis.

Despite the uniform AKI criteria that have been developed, AKI remains a clinical diagnosis and has to be put into the clinical context where it occurs. The AKI criteria should not be used by the clinician as an absolute ‘truth’, but rather as a frame for decisions, for example, on when to initiate measures aimed at preventing further damage to the kidney.

### Kidney injury biomarkers

By the time KDIGO SCR criteria for AKI are met, the decline in glomerular filtration rate (GFR) and likely structural damage that preceded that decline have been present for several hours. It has been hypothesized that delayed detection of AKI is one of the reasons why intervention trials aimed at treating AKI have failed. Therefore, a lot of effort has been put into finding biomarkers that could detect kidney injury earlier, before functional biomarkers (SCr and serum cystatin C) have changed, and which would be related to the clinical course of AKI, predict the need of dialysis, or other complications. These biomarkers provide information on tubular injury, which commonly precedes functional decline. In Table 2, the most well-studied biomarkers are summarized. Of these, liver-type fatty acid-binding protein (L-FABP) is approved for use in Japan, neutrophil gelatinase-associated lipocalin (NGAL) may be used in some localities in Europe and the combination of tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP-7) is approved for use in the USA.

Early studies that found biomarkers to be useful in detecting established AKI [10–13, 16] were followed by large prospective studies [14, 17–23]. NGAL and interleukin 18 (IL-18), both in plasma and urine, were tested as early markers of injury following cardiac surgery [17, 18, 22, 23]. However, the ability of any of these markers to predict AKI was modest.

Recently, the combination of two biomarkers for tubular cell cycle arrest, TIMP-2 and IGFBP-7, has shown promising diagnostic performance to predict a doubling of SCr within 12 h in patients with sepsis [AUC (area under curve) = 0.8] [24, 25]. Both these biomarkers share the property of inducing G1 cell cycle arrest that is thought to prevent proliferation of damaged cells and thereby protecting the kidney. The strength of TIMP-2/IGFBP-7 may lie in the high negative predictive values found for excluding AKI stages 2 and 3 [14]. The test can be performed at the bedside (NephroCheck®) [26].

### Risk factors for AKI

The onset of AKI is multifactorial, and several patient-specific factors can contribute to the risk of AKI. Patients with chronic kidney disease (CKD), impaired left ventricular systolic function, advanced age commonly defined as >75 years of age, diabetes and dehydration are at particularly high risk of AKI [1, 15]. In addition, specific surgery-related factors including time spent on heart–lung machine, the use of an intra-aortic balloon pump, need for blood transfusions and hemodilution are associated with AKI [27]. Patients with CKD are not only more likely to require dialysis in conjunction with AKI, but also to develop end-stage renal disease with need for renal replacement therapy (RRT) after an episode of AKI [28]. In order to prevent AKI, it is important to identify patients at high risk before surgery or exposure to potentially nephrotoxic agents.

Several risk stratification models for AKI have been developed [29]. Commonly, these prediction models have included patient characteristics such as age, sex and renal function, and comorbidities such as diabetes and chronic obstructive pulmonary disease. A limitation of most of these studies has been that the predicted outcome has been dialysis-requiring AKI, which is a rare event [30].

Recently, two studies have investigated if a bolus dose of furosemide, the so called ‘furosemide stress test’, may predict progression of AKI stages 1–3 [31]. Furosemide is given as a single dose of 1.0 mg/kg in furosemide-naïve patients, or a dose of 1.5 mg/kg in patients with ongoing furosemide treatment. The AUC for predicting progression to stage 3 AKI was 0.87 when an output of 200 mL urine for the first 2 h was used as cutoff, which is a much higher AUC than any kidney injury biomarker has achieved. In a recent study, eight prediction models for AKI after cardiac surgery were investigated, and found to have poor or modest abilities to predict a postoperative SCr elevation of >50%, with AUCs between 0.65 and 0.75 [32].

### Table 1. KDIGO’s criteria for acute kidney injury [1]

| Stage | Increase in serum creatinine | Urine output |
|-------|------------------------------|--------------|
| 1     | ≥0.3 mg/dL (26.5 μmol/L) within 48 h or 1.5–1.9 times baseline within 7 days | <0.5 mL/kg/h for 6–12 h |
| 2     | 2.0–2.9 times baseline within 7 days | <0.5 mL/kg/h for ≥12 h |
| 3     | ≥3.0 times baseline, or ≥4.0 mg/dL (354 μmol/L) increase within 7 days or initiation of RRT or | <0.3 mL/kg/h for ≥24 h or Anuria ≥12 h |
|       | in patients <18 years of age, decrease in estimated GFR to <35 mL/min/1.73 m² | |
The association between antinflammatory drugs (NSAID), several antimicrobials and several chemotherapeutic agents [38]. The incidence of AKI ranges from 2.6% to 13% [37]. Drugs unknown, and the underlying causes are not examined.

Common causes of AKI

The definition of AKI does not include its etiology and it is diagnosed as a single entity, regardless of pathogenesis (Figure 1). However, it is important to determine the cause of AKI to improve patient outcomes. Historically, the etiology of AKI was divided into three categories: prerenal, renal and postrenal. The combination of prerenal and renal causes of AKI is common, for example, in sepsis or cardiac surgery. There is an underdiagnosis of AKI, and missed AKI is associated with a worse prognosis [36]. In many cases, AKI is identified at late stages or remains unknown, and the underlying causes are not examined.

Contrast-induced AKI (CI-AKI) after coronary angiography is relatively common with an incidence of 2.6% to 13% [37]. Drugs associated with AKI are, among others, nonsteroidal anti-inflammatory drugs (NSAID), several antimicrobials and several chemotherapeutic agents [38]. The association between angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers and AKI in patients who undergo surgery is controversial. Some studies have found an increased risk [39], others no increased risk [40], and yet further studies a decreased risk of AKI among treated patients [41]. Drug-induced AKI can, in most cases, be alleviated by replacing the nephrotoxic drug with a similar less-nephrotoxic drug, or changing administration practices.

Noncardiac surgery is thought to be associated with a lower risk of AKI than cardiac surgery [42]. However, AKI in noncardiac surgery patients is largely understudied. In one study where AKI was defined as a >50% increase in SCr levels after noncardiac surgery, 7% developed AKI [43]. In patients undergoing cardiac surgery the incidence of AKI is between 1% and 50% depending on the type of procedure and the classification of AKI [2]. AKI is common in patients with sepsis, and patients with septic shock and AKI have an almost doubled in-hospital mortality [44].

Prerenal AKI

Prerenal AKI occurs because plasma flow and intraglomerular pressure are inadequate to maintain filtration capacity. The most common cause is hypovolemia, followed by a decreased cardiac output or impaired autoregulation, which may be induced by NSAIDs. Prerenal AKI is usually reversible in terms of normalizing baseline SCr, but may still involve an injury. The autoregulation of the pre- and postglomerular arterioles are required both for adequate renal blood flow and to maintain hydrostatic pressure in the glomeruli.

Postrenal AKI

Postrenal AKI is caused by an obstruction of urinary flow. A number of causes exist as benign prostatic hyperplasia, urethral stricture, pelvic or abdominal cancers, neurological causes as multiple sclerosis, ureter obstruction from kidney stones or ureter injury following surgery or trauma [35, 44]. The initial action is to exclude urinary outflow obstruction, and thereafter,

### Table 2. Biomarkers of acute kidney injury

| Type of biomarker | Biomarker | Description | Kinetics |
|------------------|-----------|-------------|---------|
| Tubular injury   | Kidney injury molecule 1 [10] | Tested in urine. Upregulated after injury to proximal tubuli. Activates immune cells leading to clearance and remodeling of injured cells. | Detected 12–24 h after injury, and will peak at 48–72 h post-injury |
|                  | IL-18 [11] | Tested in urine and serum. Upregulated after ischemic injury to proximal tubuli. Has pro-inflammatory characteristics. | Detected within the first 6 h after injury, and will peak at 12–18 h post-injury |
|                  | NGAL [12] | Tested in urine and serum. Is released both from distal and proximal tubuli from damaged cells and acts protective enzymes, and prevents production of radicals. NGAL is also released from liver and neutrophils in sepsis. | Detected within 3 h of injury, and will peak at 6 h post-injury |
|                  | L-FABP [13] | Tested in urine. Protein that is expressed in proximal tubuli after ischemic injury. | Detected within 1 h after injury, and will peak within 6 h post-injury |
|                  | TIMP-2 and IGFBP-7 [14] | Tested in urine. Both these biomarkers induce G1 cell cycle arrest that prevents proliferation of endothelial cells. | Detected within 12 h of injury |
| Glomerular filtration | Cystatin C [15] | Tested in serum. Protein, which is produced at a constant rate and filtered freely, re-absorbed and metabolized in the proximal tubuli. | Detected 12–24 h after injury, and will peak within 48 h post-injury |
ultrasound should be performed to rule out hydronephrosis [26]. In cases where flank pain is present, the preferred imaging should be computed tomography without contrast in order to rule out kidney stones.

Renal AKI
Renal AKI may be linked to nephrotoxic drugs, other nephrotoxins, infection, sepsis, renal ischemia, malignant hypertension or inflammation (e.g., glomerulonephritis, vasculitis, allergic reaction). In the absence of a clear cause of AKI, inadequate response to treatment, or findings of both hematuria and proteinuria in patients with AKI, inflammatory diseases of the renal parenchyma such as glomerulonephritis and vasculitis should be suspected [26].

Combination of prerenal and renal AKI
In many cases, prerenal and renal AKI exist concurrently. AKI may occur in sepsis, despite the absence of hypotension. The causes are multifactorial including sympathetic activation, and hormonal and inflammatory mediation [45]. Concomitant prerenal and renal AKI is also observed in disorders such as rhabdomyolysis, and hypercalcemia, in which severe hypovolemia combined with the toxic effects of myoglobin and calcium causes AKI [46]. Rhabdomyolysis is commonly associated with hypovolemia, thus leading to prerenal AKI, and direct nephrotoxic effects of myoglobin and heme proteins, and may also lead to intraluminal cast formation and tubular obstruction. After cardiac surgery the causes of AKI are often a combination of ischemia, inflammation, hypotension, embolism, and free hemoglobin from blood transfusions.

Treatment and management of AKI
General principles
The treatment of AKI is aimed at limiting damage and preventing further loss of GFR. There are several key principles to follow, where the most important are to treat the underlying cause, and to achieve normovolemia and hemodynamic stability. In addition, electrolyte disturbances should be treated, nephrotoxic drugs discontinued or dose-adjusted, and drugs with renal elimination should be dose-adjusted [47]. Potassium-sparing diuretics and ACE inhibitors should be discontinued in order to avoid progression of AKI and hyperkalemia. Acid–base disturbances, mainly in the form of metabolic acidosis, are frequent in moderate to severe AKI (stages 2 and 3), where treatment of the underlying causes is the primary objective. A cornerstone of the management of all patients with AKI is to monitor urine output, and to initially monitor SCr several times a day.

Hemodynamic optimization
Fluid therapy
For all cases in which hypovolemia is the suspected cause of AKI, the first priority is to restore fluid balance with the aim to increase cardiac output, in order to stabilize hemodynamics, and renal blood flow, without inducing fluid overload. Evaluation of hydration status is difficult, and several methods have recently become available in clinical practice such as measuring bioimpedance and ultrasound assessment of vena cava and left ventricle dimensions [48]. The rate of rehydration should be individually assessed [49].

Choice of fluid
Several studies have shown that crystalloid solutions with high chloride content may be harmful and lead to a deterioration of renal function [50, 51]. It is thought that high chloride concentration at the macula densa increases tubuloglomerular feedback causing pregglomerular vasoconstriction and decreased renal perfusion [51]. A recent meta-analysis found an association between resuscitation with fluids containing high chloride content and increased risk of AKI, metabolic acidosis and time on mechanical ventilation [52]. However, a recently published randomized trial in the intensive-care setting found no difference in the risk of AKI or dialysis in patients treated with saline compared with a balanced crystalloid solution [53]. In studies where the synthetic colloid hydroxyethyl starch has been used in sepsis and critically ill patients, an increased risk of AKI has...
been found, leading to cessation of its use [54]. Albumin is considered to be harmless to the kidney, but its advantage over crystalloid solutions has not been demonstrated [49]. In conclusion, current knowledge suggests that patients with AKI, in need of fluid therapy, should be treated with a balanced crystalloid solution.

**Fluid overload**
It has long been believed that infusion of large volumes of fluids can treat or prevent AKI by maintaining renal perfusion and urine output. This was further fueled by a study published 15 years ago where so called ‘early goal-directed therapy’, including infusion of generous amounts of fluids, was found to increase survival in patients with severe sepsis [55]. However, in the last decade this has been challenged in a number of studies that have demonstrated harm from excess fluids [48, 56, 57]. Recently, in a randomized controlled trial (RCT), it was found that ‘permissive oliguria’ after major abdominal surgery was not associated with higher NGAL levels or lower measured GFR compared with usual care [58]. Fluid overload may lead to an increased intra-abdominal pressure, and edema in the kidney that is surrounded by a nonexpandable fibrous capsule, thereby reducing perfusion pressure in the kidney [59, 60]. Current sepsis guidelines [61] recommend that the target central venous pressure should be 8 mmHg, a level that may lead to decreased renal perfusion and AKI [62]. In order to prevent fluid overload, a new strategy of fluid resuscitation has been proposed by the Acute Dialysis Quality Initiative that consists of four phases: the rescue, optimization, stabilization and de-escalation phases [63]. In the rescue phase, boluses of fluid are administered in life-threatening hemodynamic instability; in the optimization phase, when the patient is hemodynamically stable, careful administration of fluids is done with the aim to maintain hemodynamic stability; in the stabilization phase, when the patient is in a stable condition, a zero or negative fluid balance is aimed for; and finally, in the de-escalation phase, excess fluid is removed.

**Vasoactive drugs**
Vasoactive drugs lead to systemic vasconstriction and an increased pressure that increases renal perfusion [64]. A moderate dose of norepinephrine is thought to reduce the risk of AKI in patients with vasodilated shock [64, 65]. However, this has been challenged in a recently published study [66]. In animal studies, norepinephrine administration has been found to increase renal blood flow and GFR [64]. Moreover, an increase in mean arterial blood pressure from 60 to 75 mmHg using norepinephrine resulted in an increase in GFR and renal oxygen delivery in patients with vasodilated shock after cardiac surgery [67]. A higher mean arterial pressure has also been shown to reduce the need for dialysis in sepsis patients [66].

Dopamine is a renal vasodilator acting on both the pre- and postglomerular arterioles and thereby increasing renal blood flow. The administration of a low dose of dopamine has been thought to increase renal perfusion. However, studies have not shown a beneficial effect in treating or preventing AKI and adverse effects such as arrhythmic events have been identified [1, 26]. Therefore, the recommendation currently is not to use dopamine in patients with AKI [26, 47, 68].

Vasopressin is another drug that increases blood pressure, and is commonly used as a second-line drug in conjunction with norepinephrine in order to stabilize hemodynamics. In one study where norepinephrine was compared with norepinephrine in combination with vasopressin, the authors found a trend toward a lower risk of AKI in the combination group [69].

The inotropic and vasodilating drug levosimendan increases cardiac output, and may be used when a restricted fluid therapy is warranted in patients with compromised cardiac function [70]. Levosimendan is a calcium sensitizer, and unlike several vasopressor drugs, it improves right ventricular function, which reduces central venous pressure leading to reduced venous statsis in the kidney. Furthermore, levosimendan dilates preglomerular arterioles, improving renal circulation [71]. The renal effects of levosimendan are under investigation [72].

**Drug treatment for AKI**
Several drugs have been tested for AKI, but none has been established as standard treatment in clinical practice. Many studies have been underpowered and results have been inconsistent. The most-studied treatments for AKI are discussed below.

**Diuretics**
Furosemide has several renoprotective characteristics like blocking of oxygen-consuming sodium channels in the tubules, increased diuresis leading to a reduced oxygen demand in the kidney and washout of kidney-toxic molecules [73]. However, clinical studies have failed to demonstrate that furosemide improves the prognosis in AKI, except in patients with fluid overload [74]. The use of furosemide as prevention of AKI in conjunction with cardiac surgery or contrast exposure has been linked to a higher risk of AKI [75].

**Acetylcysteine**
The protective effect of acetylcysteine is considered to be mainly related to its antioxidant properties, but also inducing vasodilation in the renal medulla by stabilizing nitric oxide and by inhibiting ACE [76]. Acetylcysteine has not been shown to prevent AKI associated with cardiac surgery or in patients with sepsis [77, 78]. In the setting of CI-AKI, results have been contradictory, but several meta-analyses suggest that acetylcysteine provides some protection against CI-AKI, especially in patients at high risk [76, 79, 80]. Due to the heterogeneity of study results, it is difficult to establish a clear consensus, but the KDIGO work group has proposed that oral acetylcysteine along with intravenous isotonic crystalloid solutions should be used in patients at high risk of CI-AKI [68].

**Sodium bicarbonate**
Sodium bicarbonate has been used for the treatment and prevention of AKI associated with heme-pigment nephropathies (myoglobin, hemoglobin and bilirubin), and in tumor lysis syndrome. Sodium bicarbonate is thought to increase the solubility of these products preventing the formation of obstructive methemoglobin cylinders and crystals in the tubules [81]. In addition, sodium bicarbonate is thought to reduce oxidative stress and free radicals [81]. This led to the hope that sodium bicarbonate may prevent AKI. A pilot study that included 100 cardiac surgery patients randomized either to sodium bicarbonate or crystalloids found a reduced risk of AKI in the intervention arm [82]. However, in the full-scale RCT no preventive effect of sodium bicarbonate was found, but instead in an intention-to-treat analysis there was a significant association between sodium bicarbonate and an increased risk of AKI [83]. Similarly, another trial reported no preventive effects of sodium bicarbonate [84].
prevention of CI-AKI, sodium bicarbonate solutions have not shown to be superior compared with sodium chloride solutions [26]. Thus, sodium bicarbonate is not recommended for the prevention or treatment of AKI currently [81, 85].

Statins
Statins, which are used to prevent cardiovascular events, are thought to reduce free oxygen radicals in the renal tubules and to modulate inflammatory responses, which has led to the assumption that statins may prevent AKI. In a paper published in 2012 it was found that a high dose (80 mg) of atorvastatin before administration of contrast agent was associated with a lower risk of CI-AKI [86]. Later, an RCT on perioperative atorvastatin therapy found no preventive effect of AKI after cardiac surgery [87]. Moreover, recently an RCT on perioperative rosuvastatin treatment found an increased risk of AKI in the rosuvastatin group [88]. Similarly, another RCT on patients with sepsis-associated acute respiratory distress syndrome concluded that rosuvastatin was associated with the secondary outcome of persistent AKI [89]. Regarding CI-AKI, a recent meta-analysis of studies on statin-naive patients undergoing coronary angiography showed that statin treatment before contrast exposure may have a protective effect [90]. Due to these conflicting results, statin therapy for AKI prevention is not currently recommended.

Remote ischemic preconditioning
Remote ischemic preconditioning (RIPC) is a procedure of short episodes of ischemia induced at a remote site, which is thought to induce ischemic-protective mechanisms to other organs such as the kidney [91]. The underlying mechanisms are not fully understood, but a recent study suggested that inducement of cell cycle arrest in renal tubuli may be a potential mechanism [91]. In cardiac surgery populations, results of RIPC have been contradictory. In an early RCT in 120 patients, it was found that RIPC was associated with a lower risk of AKI [92]. In a later RCT in 240 patients undergoing cardiac surgery with a high risk of AKI, a similar finding was reported [93]. However, other studies have found no preventive effects of RIPC for AKI in patients undergoing cardiac surgery [94, 95]. Two smaller studies demonstrated a reduction in CI-AKI after the use of RIPC [96, 97]. Since data are inconclusive and contradictory, there is currently no firm recommendation to use RIPC to prevent AKI.

Dialysis
The current recommendation on when to start RRT involves life-threatening changes in fluids, electrolytes, the acid–base balance or uremic complications [1]. However, controversy exists over the benefit of initiating dialysis at an early stage, when life-threatening complications have not yet developed, versus later stage [98]. The accumulated data from clinical trials with varying quality and observational studies have not concluded an optimal timing for start of RRT. A recent RCT [The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial] found that early versus delayed RRT in the intensive care unit offered no benefit in terms of outcome [99]. While the most recent randomized trial [the Early vs Late Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury (ELAIN) trial] showed that early initiation of continuous RRT reduced mortality, hospital length of stay and duration of RRT compared with those with late initiation [100]. Interestingly, the late initiation group in the ELAIN trial resembled the early initiation group in the AKIKI trial, and may explain the contradictory results.

Summary
AKI is common and associated with poor outcomes. Despite a number of intervention studies, no effective treatment or prevention of AKI has been found. Therefore, efforts should be made to limit damage in patients with AKI by use of crystalloid solutions instead of fluids with a high chloride content, avoiding fluid overload, and discontinuing or dose-adjusting nephrotoxic drugs. In addition, if the cause of AKI is not obvious, postrenal outflow obstruction and medication-induced AKI have to be excluded in order to prevent further damage to the kidney.

Acknowledgements
This study was funded by a grant from the Swedish Medical Society (SLS-177331).

Conflict of interest statement
This article is not under consideration elsewhere and none of the content has been previously published. All authors have read and approved the manuscript and there is no disclosure of any potential conflict of interest. M.J.H. has received consulting honoraria from Actelion and Pfizer.

References
1. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17: 204
2. Pickering JW, James MT, Palmer SC. Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies. Am J Kidney Dis 2015; 65: 283–293
3. Bagshaw SM, George C, Gibney RTN et al. A multi-center evaluation of early acute kidney injury in critically ill trauma patients. Ren Fail 2008; 30: 581–589
4. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–R212
5. Mehta RL, Kellum JA, Shah SV et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
6. Md Raïb A, Pickering JW, Shaw GM et al. The urine output definition of acute kidney injury is too liberal. Crit Care 2013; 17: R112
7. Bouchard J, Soroko SB, Chertow GM et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76: 422–427
8. Kellum JA, Sileanu FE, Murugan R et al. Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol 2015; 26: 2231–2238
9. Brown JR, Kramer RS, Coca SG et al. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg 2010; 90: 1142–1148
10. Han WK, Bailly V, Abichandani R et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237–244
11. Melnikov VY, Eder T, Fantuzzi G et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001; 107: 1145–1152
12. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 2003; 14: 2534–2543

13. Yamamoto T, Noiri E, Ono Y et al. Renal L-type fatty acid-binding protein in acute ischemic injury. *J Am Soc Nephrol* 2007; 18: 2894–2902

14. Kashani K, Al-Khafaji A, Ardiles T et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. *Crit Care* 2013; 17: R25

15. National Clinical Guideline Centre (UK). *Acute Kidney Injury: Prevention, Detection and Management up to the Point of Renal Replacement Therapy* [Internet], National Institute for Health and Clinical Excellence: Guidance. London: Royal College of Physicians, 2013. [http://www.ncbi.nlm.nih.gov/books/NBK247665/ (13 June 2016, date last accessed)

16. Wellwood JM, Dent CL, Ma Q et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. *Biomarkers* 2007; 22: 2089–2095

17. Bennett M, Dent CL, Ma Q et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. *Clin J Am Soc Nephrol* 2008; 3: 665–673

18. Liangos O, Tighiouart H, Perianayagam MC et al. Plasma gelatinase-associated lipocalin as a novel early urinary biomarker for acute kidney injury in critically ill adults. *J Am Soc Nephrol* 2009; 20: 1823–1832

19. Cruz DN, deCal M, Garzotto F et al. Plasma gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. *Intens Care Med* 2010; 36: 444–451

20. Siew ED, Ware LB, Gebretsadik T et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. *J Am Soc Nephrol* 2009; 20: 1823–1832

21. Bennett M, Dent CL, Ma Q et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. *Clin J Am Soc Nephrol* 2008; 3: 665–673

22. Siew ED, Ikizler TA, Gebertssadik T et al. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. *Clin J Am Soc Nephrol* 2010; 5: 1497–1505

23. Zapettelli M, Krawczeski CD, Passik CS et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. *J Am Soc Nephrol* 2011; 22: 1748–1157

24. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 2005; 365: 1231–1238

25. Hoste EAJ, McCullough PA, Kashani K et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. *Nephrol Dial Transplant* 2014; 29: 2054–2061

26. Bihorac A, Chawla LS, Shaw AD et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. *Am J Respir Crit Care Med* 2014; 189: 932–939

27. Endre ZH, Pickering JW. Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis. *Nat Rev Nephrol* 2014; 10: 683–685.

28. Parolari A, Pesce LL, Pacini D et al. Risk factors for perioperative acute kidney injury after adult cardiac surgery: role of perioperative management. *Ann Thorac Surg* 2012; 93: 584–591

29. Rydén L, Sartipy U, Evans M et al. Acute kidney injury after coronary artery bypass grafting and long-term risk of end-stage renal disease. *Circulation* 2014; 130: 2005–2011

30. McMahon BA, Koyner JL. Risk Stratification for acute kidney injury: are biomarkers enough? *Adv Chronic Kidney Dis* 2016; 23: 167–178

31. Ivert T, Holzmann MJ, Sartipy U. Survival in patients with acute kidney injury requiring dialysis after coronary artery bypass grafting. *Eur J Cardiothorac Surg* 2014; 45: 312–317

32. Chawla LS, Davison DL, Brasha-Mitchell E et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. *Crit Care* 2013; 17: R207

33. Kiers HD, van den Boogaard M, Schoenmakers MQ et al. Comparison and clinical suitability of eight prediction models for cardiac surgery-related acute kidney injury. *Nephrol Dial Transplant* 2013; 28: 345–351

34. Emamian SA, Nielsen MB, Pedersen JF et al. Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. *AJR Am J Roentgenol* 1993; 160: 83–86

35. Perazella MA. The urine sediment as a biomarker of kidney disease. *Am J Kidney Dis* 2015; 66: 748–755

36. Wiikar S, Bonventre J. Acute kidney injury. In: Kasper DL (ed). *Harrison's Principles of Internal Medicine*, 19th edn. Chapter 334. New York, NY: McGraw Hill Education, 2015

37. Meran S, Wonnacott A, Amphlett B et al. How good are we at managing acute kidney injury in hospital? *Clin Kidney J* 2014; 7: 144–150

38. Cortese B, Scialbasi A, Sebib E et al. Comparison of risk of acute kidney injury after primary percutaneous coronary interventions with the transradial approach versus the transfemoral approach (from the PRIPITENA urban registry). *Am J Cardiol* 2014; 114: 820–825

39. Joyce EL, Kane-Gill SL, Fuhrman DY et al. Drug-associated acute kidney injury: who’s at risk? *Pediatr Nephrol* Berl Ger 2016

40. Arora P, Rajagopalam S, Ranjan R et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. *Clin J Am Soc Nephrol* 2008; 3: 1266–1273

41. Ouzounian M, Buth KJ, Valeeva L et al. Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery. *Ann Thorac Surg* 2012; 93: 559–564

42. Benedetto U, Siciarretta S, Roscito A et al. Preoperative angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. *Ann Thorac Surg* 2008; 86: 1160–1165

43. Grams ME, Sang Y, Coresh J et al. Acute kidney injury after major surgery: a retrospective analysis of veterans health administration data. *Am J Kidney Dis* 2016; 67: 872–880

44. Biteker M, Dayan A, Tekkeşin A et al. Incidence, risk factors, and outcomes of perioperative acute kidney injury in non-cardiac and nonvascular surgery. *Am J Surg* 2014; 207: 53–59

45. Bagshaw SM, Lapinsky S, Dial S et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. *Intens Care Med* 2009; 35: 871–881

46. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis. *J Clin Invest* 2014; 124: 2355–2363

47. Jindal A, Nayak S. Myoglobinuria and acute kidney injury. *J Integ Nephrol Androl* 2015; 2: 50

48. Harty J. Prevention and management of acute kidney injury. *Ulster Med J* 2014; 83: 149–157

49. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. *Nat Rev Nephrol* 2014; 10: 37–47

50. Moritz ML, Ayus JC. Maintenance intravenous fluids in acutely ill patients. *N Engl J Med* 2015; 373: 1350–1360
50. Chowdhury AH, Cox EF, Francis ST et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308: 1566–1572
51. Chowdhury AH, Cox EF, Francis ST et al. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256: 18–24
52. Krajewski ML, Raghunathan K, Paluszkiewicz SM et al. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. Br J Surg 2015; 102: 24–36
53. Young P, Bailey M, Beasley R et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the split randomized clinical trial. JAMA 2015; 314: 1701–1710
54. Perner A, Haase N, Guttormsen AB et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367: 124–134
55. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–1377
56. Teixeira C, Garzotto F, Piccinni P et al. Fluid balance and urine volume are independent predictors of mortality in acute kidney injury. Crit Care 2013; 17: R14
57. Vaara ST, Korhonen A-M, Kaukonen K-M et al. Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. Crit Care 2012; 16: R197
58. Puckett JR, Pickering JW, Palmer SC et al. Low versus standard urine output targets in patients undergoing major abdominal surgery: a randomized noninferiority trial. Ann Surg 2016doi: 10.1097/SLA.0000000000002044
59. Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol 2011; 22: 615–621
60. Wouters J, Claus P, Brossena N et al. Pathophysiology of renal hemodynamics and renal cortical microcirculation in a porcine model of elevated intra-abdominal pressure. J Trauma 2009; 66: 713–719
61. Dellinger RP, Carlet JM, Masur H et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intens Care Med 2004; 30: 536–555
62. Legrand M, Dupuis C, Simon C et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 2013; 17: R278
63. Hoste EA, Maitland K, Brudney CS et al. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth 2014; 113: 740–747
64. Bellomo R, Kellum JA, Wisniewski SR et al. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999; 159: 1186–1192
65. Haase M, Bellomo R, Story D et al. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. Nephrol Dial Transplant 2012; 27: 153–160
66. Lankadeva YR, Kosaka J, Evans RG et al. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. Kidney Int 2016; 90: 100–108
67. Redfors B, Bragadottir G, Sellgren J et al. Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury. Intens Care Med 2011; 37: 60–67
68. International Society of Nephrology. Summary of recommendation statements (KDIGO clinical practice guideline for acute kidney injury). Kidney Int Suppl 2012; 2: 341–342
69. Gordon AC, Russell JA, Walley KR et al. The effects of vasopressin on acute kidney injury in septic shock. Intens Care Med 2010; 36: 83–91
70. Bove T, Matteazzi A, Belletti A et al. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Heart Lung Vessels 2015; 7: 35–46
71. Yilmaz MB, Grossini E, Silva Cardoso JC et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther 2013; 27: 581–590
72. Orme RML, Perkins GD, McAuley DF et al. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oGan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials 2014; 15: 199
73. Ricksten SE, Bragadottir G, Redfors B. Renal oxygenation in critically ill patients with renal replacement therapy—a vexed issue. N Engl J Med 2010; 362: 83–91
74. Ahmed US, Iqbal HI, Akbar SR. Furosemide in acute kidney injury—a vexed issue. Austin J Nephrol Hypertens 2014; 1: 1025
75. Patel NN, Angelini GD. Pharmacological strategies for the prevention of acute kidney injury following cardiac surgery: an overview of systematic reviews. Curr Pharm Des 2014; 20: 5484–5488
76. Liu R, Nair D, Ix J et al. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005; 20: 193–200
77. Adabag AS, Ishani A, Koneswaran S et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J 2008; 155: 1143–1149
78. Song JW, Shim JK, Soh S et al. Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass. Nephrol (Carlton Vic) 2015; 20: 96–102
79. Wu M-Y, Hsiang H-F, Wong C-S et al. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol 2013; 45: 1309–1318
80. Wang N, Qian P, Kumar S et al. The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 2016; 209: 319–327
81. Schiff I. Sodium bicarbonate infusion for prevention of acute kidney injury: no evidence for superior benefit, but risk for harm? Int Urol Nephrol 2015; 47: 321–326
82. Haase M, Haase-Fieltz A, Bellomo R et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009; 37: 39–47
83. Haase M, Haase-Fieltz A, Plass M et al. Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial. PLoS Med 2013; 10: e1001426
84. McGuinness SP, Parke RL, Bellomo R et al. Sodium bicarbonate infusion to reduce cardiac surgery-associated acute
kidney injury: a phase II multicenter double-blind randomized controlled trial. Crit Care Med 2013; 41: 1599–1607

85. Lameire N, Kellum JA, KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 2013; 17: 205

86. Quintavalle C, Fiore D, De Micco F et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126: 3008–3016

87. Billings FT, Hendricks PA, Schildcrout JS et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 2016; 315: 877–888

88. Zheng Z, Jayaram R, Jiang L et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016; 374: 1744–1753

89. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370: 2191–2200

90. Gandhi S, Mosleh W, Abdel-Qadir H et al. Statins and contrast-induced acute kidney injury with coronary angiography. Am J Med 2014; 127: 987–1000

91. Gassanov N, Nia AM, Caglayan E et al. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol 2014; 25: 216–224

92. Zimmerman RF, Ezeanuna PU, Kane JC et al. Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. Kidney Int 2011; 80: 861–867

93. Zarbock A, Schmidt C, Van Aken H et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 2015; 313: 2133–2141

94. Gallagher SM, Jones DA, Kapur A et al. Remote ischemic preconditioning has a neutral effect on the incidence of kidney injury after coronary artery bypass graft surgery. Kidney Int 2015; 87: 473–481

95. Hausenloy DJ, Candilio L, Evans R et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 2015; 373: 1408–1417

96. Igarashi G, Iino K, Watanabe H et al. Remote ischemic preconditioning alleviates contrast-induced acute kidney injury in patients with moderate chronic kidney disease. Circ J 2013; 77: 3037–3044

97. Yamanaka T, Kawai Y, Miyoshi T et al. Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction: a randomized controlled trial. Int J Cardiol 2015; 178: 136–141

98. Ricci Z, Ronco C. Renal replacement therapy in the critically ill: getting it right. Curr Opin Crit Care 2012; 18: 607–612

99. Gaudry S, Hajage D, Schortgen F et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375: 122–133

100. Zarbock A, Kellum JA, Schmidt C et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 2016; 315: 2190–2199